Reviewing Foamix Pharmaceuticals Ltd. (FOMX)’s and Rubius Therapeutics Inc. (NASDAQ:RUBY)’s results

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) and Rubius Therapeutics Inc. (NASDAQ:RUBY), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Foamix Pharmaceuticals Ltd. 3.00M 48.85 63.39M -1.38 0.00
Rubius Therapeutics Inc. N/A 0.00 107.36M -1.12 0.00

Table 1 demonstrates Foamix Pharmaceuticals Ltd. and Rubius Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides Foamix Pharmaceuticals Ltd. and Rubius Therapeutics Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Foamix Pharmaceuticals Ltd. -2,113.00% -79.5% -68.8%
Rubius Therapeutics Inc. 0.00% -52.6% -26.4%

Liquidity

Foamix Pharmaceuticals Ltd. has a Current Ratio of 9 and a Quick Ratio of 9. Competitively, Rubius Therapeutics Inc.’s Current Ratio is 20.7 and has 20.7 Quick Ratio. Rubius Therapeutics Inc.’s better ability to pay short and long-term obligations than Foamix Pharmaceuticals Ltd.

Analyst Ratings

Foamix Pharmaceuticals Ltd. and Rubius Therapeutics Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Foamix Pharmaceuticals Ltd. 0 0 4 3.00
Rubius Therapeutics Inc. 0 0 0 0.00

Foamix Pharmaceuticals Ltd.’s upside potential is 522.68% at a $16.75 consensus target price.

Insider & Institutional Ownership

The shares of both Foamix Pharmaceuticals Ltd. and Rubius Therapeutics Inc. are owned by institutional investors at 0% and 94.5% respectively. Foamix Pharmaceuticals Ltd.’s share owned by insiders are 1.3%. On the other hand, insiders owned about 8.4% of Rubius Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Foamix Pharmaceuticals Ltd. -14.38% -27.17% -26.17% -39.37% -48.85% -25.35%
Rubius Therapeutics Inc. 3.88% -13.94% 14.66% 0.7% 0% -1.74%

For the past year Foamix Pharmaceuticals Ltd.’s stock price has bigger decline than Rubius Therapeutics Inc.

Summary

Rubius Therapeutics Inc. beats on 6 of the 10 factors Foamix Pharmaceuticals Ltd.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Sebela Pharmaceuticals Inc.; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.